Clinical Trial

Phase III Study of AK112 for NSCLC Patients

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-05-01; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2024-09-16
Trial Details
NCT Number NCT06396065
Lead Sponsor Summit Therapeutics
Collaborators: Akeso
Conditions Non-Squamous Non-small Cell Lung Cancer
Enrollment 420 participants
Start Date 2023-05-04
Primary Completion 2025-04-12 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28